OCX 0247Alternative Names: OCX 247
Latest Information Update: 27 Sep 2001
At a glance
- Originator Vion Pharmaceuticals
- Mechanism of Action Alkylating agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Sep 2001 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 15 Oct 1998 Preclinical development for Cancer in USA (Unknown route)
- 15 Oct 1998 New profile